Sunitinib maleate

被引：129

作者：

Atkins, M

Jones, CA

Kirkpatrick, P

机构：

[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 04期

关键词：

D O I：

10.1038/nrd2012

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Sunitinib maleate (Sutent; Pfizer) is a small-molecule inhibitor of multiple receptor tyrosine kinases involved in cancer, including vascular endothelial growth factor receptors, platelet-derived growth factor receptors and the KIT receptor. It was approved by the US FDA for the treatment of gastrointestinal stromal tumours and advanced renal-cell carcinoma in January 2006.

引用

页码：279 / 280

页数：2

共 13 条

[1] Innovations and challenges in renal cancer: Consensus statement from the first international conference [J].

Atkins, MB ;

Avigan, DE ;

Bukowski, RM ;

Childs, RW ;

Dutcher, JP ;

Eisen, TG ;

Figlin, RA ;

Finke, JH ;

Flanigan, RC ;

George, DJ ;

Goldberg, SN ;

Gordon, MS ;

Iliopoulos, O ;

Kaelin, WG ;

Linehan, WM ;

Lipton, A ;

Motzer, RJ ;

Novick, AC ;

Stadler, WM ;

Teh, BT ;

Yang, JC ;

King, L .

CLINICAL CANCER RESEARCH, 2004, 10 (18) :6277S-6281S

[2] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[3] Renal-cell carcinoma [J].

Cohen, HT ;

McGovern, FJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490

[4] Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571) [J].

Demetri, GD .

EUROPEAN JOURNAL OF CANCER, 2002, 38 :S52-S59

[5]

ESCUDIER B, 2005, P AM SOC CLIN ONCO A, V4510

[6] Tyrosine kinases as targets for cancer therapy [J].

Krause, DS ;

Van Etten, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :172-187

[7]

Mendel DB, 2003, CLIN CANCER RES, V9, P327

[8] Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [J].

Motzer, RJ ;

Michaelson, MD ;

Redman, BG ;

Hudes, GR ;

Wilding, G ;

Figlin, RA ;

Ginsberg, MS ;

Kim, ST ;

Baum, CM ;

DePrimo, SE ;

Li, JZ ;

Bello, CL ;

Theuer, CP ;

George, DJ ;

Rini, BI .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :16-24

[9]

MOTZER RJ, 2005, P AM SOC CLIN ONCO A, V4508

[10]

RINI B, 2005, P AM SOC CLIN ONCO A, V4509

← 1 2 →